Employer-Paid

Finding innovative ways to get a handle on pharmaceutical spending is a top priority for employers.

Nearly half of American families have a nonelderly adult member with a pre-existing health condition.

Cost may be a major issue limiting adoption of gene therapy, but it's not the only one.

That equates to an estimated $760 billion to $935 billion every year in wasteful health care spending.

How can employers be confident they are offering the right coverage to employees and their families?

Morningstar study of youthful HSA industry finds some funds still costly, some investment menus still cluttered, and some fail basic transparency standards.